CV SciencesCVSI +9.09% OCF Yield % is -4.60 as of Jun. 27, 2026. The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, CV Sciences ranks worse than 81.19% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
CV Sciences OCF Yield % Related Terms
CV Sciences OCF Yield % Historical Data
* Premium members only.
The historical data trend for CV Sciences's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CV Sciences OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CV Sciences's OCF Yield % distribution charts can be found below:
* The bar in red indicates where CV Sciences's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CV Sciences (CVSI) has a OCF Yield % of -4.60 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on CV Sciences and its competitors. According to the industry distribution chart, CV Sciences ranks #816 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 81.2%.
Is CV Sciences' OCF Yield % too high?
CV Sciences' current OCF Yield % is -4.60. Based on the distribution chart, CV Sciences ranks #816 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CV Sciences' OCF Yield % compare to INM and GELS?
According to the Drug Manufacturers industry distribution chart, CV Sciences ranks #816 out of 1005 companies for OCF Yield %. This places CV Sciences in the lower half of its industry. The industry median OCF Yield % is 3.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on CV Sciences and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CV Sciences's current OCF Yield % is -4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CV Sciences stock overvalued right now?
Based on GuruFocus' analysis, CV Sciences (CVSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 20% below its estimated fair value. The current OCF Yield % is -4.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For CV Sciences (CVSI), the current OCF Yield % is -4.60 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSI has been successfully added to your 